325 related articles for article (PubMed ID: 20187107)
1. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
Toso C; Merani S; Bigam DL; Shapiro AM; Kneteman NM
Hepatology; 2010 Apr; 51(4):1237-43. PubMed ID: 20187107
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
3. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
[TBL] [Abstract][Full Text] [Related]
8. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
[TBL] [Abstract][Full Text] [Related]
9. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
Yanik EL; Chinnakotla S; Gustafson SK; Snyder JJ; Israni AK; Segev DL; Engels EA
Liver Transpl; 2016 May; 22(5):627-34. PubMed ID: 26784951
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
11. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
[TBL] [Abstract][Full Text] [Related]
12. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.
Kornberg A; Küpper B; Tannapfel A; Katenkamp K; Thrum K; Habrecht O; Wilberg J
Eur J Surg Oncol; 2010 Mar; 36(3):275-80. PubMed ID: 19857941
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus in liver transplant recipients: a large single-center experience.
Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
[TBL] [Abstract][Full Text] [Related]
15. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma.
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Varo-Pérez E
Transplant Proc; 2011 Apr; 43(3):711-3. PubMed ID: 21486580
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
17. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Schnitzbauer AA; Filmann N; Adam R; Bachellier P; Bechstein WO; Becker T; Bhoori S; Bilbao I; Brockmann J; Burra P; Chazoullières O; Cillo U; Colledan M; Duvoux C; Ganten TM; Gugenheim J; Heise M; van Hoek B; Jamieson N; de Jong KP; Klein CG; Klempnauer J; Kneteman N; Lerut J; Mäkisalo H; Mazzaferro V; Mirza DF; Nadalin S; Neuhaus P; Pageaux GP; Pinna AD; Pirenne J; Pratschke J; Powel J; Rentsch M; Rizell M; Rossi G; Rostaing L; Roy A; Scholz T; Settmacher U; Soliman T; Strasser S; Söderdahl G; Troisi RI; Turrión VS; Schlitt HJ; Geissler EK
Ann Surg; 2020 Nov; 272(5):855-862. PubMed ID: 32889867
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma.
Heimbach JK
Cancer J; 2008; 14(2):95-9. PubMed ID: 18391614
[TBL] [Abstract][Full Text] [Related]
19. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
[TBL] [Abstract][Full Text] [Related]
20. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
Campbell MS; Rai J; Kozin E; Bloom RD; Markmann JF; Olthoff KM; Shaked A; Rajender Reddy K
Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]